{"entity":{"id":"nct06796907","kind":"trial","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","aka":[],"tldr":"A phase 1/2 trial of Dostarlimab and Bevacizumab in advanced solid tumours, run by GlaxoSmithKline, now recruiting.","summary":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) is a phase 1/2 interventional study registered as NCT06796907 by GlaxoSmithKline, with 305 participants planned, started 2025-03-04 and due to reach its primary completion in 2027-06-21. Interventions recorded: Mo-Rez, Dostarlimab and Bevacizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06796907","url":"https://clinicaltrials.gov/study/NCT06796907"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["dostarlimab","bevacizumab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06796907","phase":"1/2","setting":"A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors","sponsor":"GlaxoSmithKline","enrolled":305,"outcomes":[]},"route":"/trials/nct06796907/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}